The US Patent and Trademark Office (PTAB) recently ruled that CRISPR gene-editing technology belongs to the Broad Institute of Harvard and MIT, according to multiple news sources.
After an...
The Center for Breakthrough Medicines (CBM) and the University of Pennsylvania Gene Therapy Program (GCP) recently collaborated to advance the discovery and manufacturing of gene therapies.
The...
Moderna and Carisma Therapeutics recently entered into an agreement to discover, develop, and commercialize in vivo engineered chimeric antigen receptor monocyte (CAR-M) cancer...
Cosette Pharmaceuticals recently acquired US sales and distribution rights to eight prescription medications from Daiichi Sankyo Company and its affiliates.
Under the 30-month transition agreement,...
Bristol Myers Squibb and Century Therapeutics recently collaborated to develop and commercialize up to four engineered natural killer (iNK) and/or allogeneic cell therapies for hematologic malignancies...
Thermo Fisher Scientific recently completed the $1.85 billion acquisition of PeproTech to increase its capabilities in the high growth cell and gene therapy market.
PeproTech is a privately held...
Moderna and Carnegie Mellon University (CMU) recently launched its Artificial Intelligence (AI) Academy to bring mRNA therapies to patients.
The initiative will bring an immersive learning experience...
AstraZeneca recently unveiled a $1 billion state-of-the-art research and development facility to advance next-generation therapeutics, including nucleotide-based gene-editing and cell therapies.
The...
Moderna and Metagenomi recently entered into a strategic research and development collaboration to advance new gene editing systems for in vivo human therapeutic applications.
Under the terms of the...
The National Institutes of Health (NIH), FDA, ten pharmaceutical companies, and five non-profit organizations recently partnered to boost the development of gene therapies for 30 million Americans...
Francis S. Collins, MD, PhD, will be stepping down as director of the National Institutes of Health (NIH) by the end of 2021.
Collins is the longest-serving presidentially appointed NIH director,...
Thermo Fisher Scientific recently launched the integrated Gibco AAV-MAX Helper Free AAV Production System to enable scalable gene therapy workflows.
The solution aims to simplify AAV vector production...
AbbVie and Regenxbio recently partnered to develop and commercialize RGX-314, a potential one-time gene therapy to treat various chronic retinal diseases.
Researchers are currently evaluating...
Moderna recently announced that the first patient has received a dose in a Phase 1/2 study of its mRNA therapeutic, mRNA-3705, for methylmalonic acidemia (MMA).
The open-label landmark study...
AbbVie and Calico Life Sciences recently extended their collaboration to discover, develop, and bring new therapies to market for patients with age-related diseases, including neurodegeneration and...
BioNTech recently entered into an agreement with Kite, a Gilead subsidiary, to acquire its solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility to...
Gene therapy company uniQure recently entered into a pharma acquisition deal with Corlieve Therapeutics to lead its program for temporal lobe epilepsy.
The program, known as AMT-260, leverages...
CRISPR Therapeutics and Capsida Biotherapeutics recently entered into a collaboration to develop, manufacture, and commercialize gene therapies.
The companies will leverage adeno-associated...
Thermo Fisher Scientific and the University of California (UCSF) recently formed a strategic alliance to accelerate the development and manufacturing of cell-based therapies.
Under the terms of...
Biogen recently announced that its gene therapy for X-linked retinitis pigmentosa (XLRP), Cotoretigene toliparvovec (BIIB112), failed in a Phase 2/3 study.
The trial, XIRIUS, evaluated BIIB112 as a...
